scholarly journals Low-dose folic acid supplementation does not influence plasma methionine concentrations in young non-pregnant women

1999 ◽  
Vol 82 (2) ◽  
pp. 85-89 ◽  
Author(s):  
Ingeborg A. Brouwerv ◽  
Marijke van Dusseldorp ◽  
Marinus Duran ◽  
Chris M. G. Thomas ◽  
Joseph G. A. J. Hautvast ◽  
...  
Keyword(s):  
Folic Acid ◽  
Low Dose ◽  
Inverse Correlation ◽  
Folic Acid Supplementation ◽  
Vitamin B ◽  
Plasma Vitamin ◽  
Acid Supplementation ◽  
Erythrocyte Folate ◽  
Total Homocysteine ◽  
Plasma Total Homocysteine

An elevated plasma total homocysteine (tHcy) concentration is a risk factor for cardiovascular disease and for having offspring with a neural-tube defect. Folate is a methyl donor in the remethylation of homocysteine into methionine. Although folic acid supplementation decreases tHcy concentrations, effects of folic acid supplementation on plasma methionine concentrations are unclear. There is also concern that folic acid supplementation negatively affects vitamin B12 status. We studied effects of low-dose folic acid supplementation on methionine and vitamin B12 concentrations in plasma. We also investigated whether baseline plasma methionine and tHcy concentrations correlated with the baseline folate and vitamin B12 status. For a period of 4 weeks, 144 young women received either 500 μg folic acid each day, or 500 μg folic acid and placebo tablets on alternate days, or a placebo tablet each day. Plasma methionine, tHcy and plasma vitamin B12 concentrations were measured at start and end of the intervention period. Folic acid supplementation had no effect on plasma methionine or plasma vitamin B12 concentrations although it significantly decreased tHcy concentrations. Plasma methionine concentrations showed no correlation with either tHcy concentrations (Spearman rs - 0·01, P = 0·89), or any of the blood vitamin variables at baseline. Baseline tHcy concentrations showed a slight inverse correlation with baseline concentrations of plasma vitamin B12 (rs - 0·25, P < 0·001), plasma folate (rs - 0·24, P < 0·01) and erythrocyte folate (rs - 0·19, P < 0·05). In conclusion, low-dose folic acid supplementation did not influence plasma methionine or plasma vitamin B12 concentrations. Furthermore, no correlation between plasma methionine concentrations and the blood folate and vitamin B12 status was shown.

scholarly journals Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: major effect modifiers

2018 ◽  
Vol 120 (10) ◽  
pp. 1122-1130 ◽  
Author(s):  
Binyan Wang ◽  
Hongxu Wu ◽  
Youbao Li ◽  
Qianyun Ban ◽  
Xiao Huang ◽  
...  
Keyword(s):  
Folic Acid ◽  
Low Dose ◽  
Methylenetetrahydrofolate Reductase ◽  
Smoking Status ◽  
Folic Acid Supplementation ◽  
Major Effect ◽  
Acid Supplementation ◽  
Total Homocysteine ◽  
Using Data

AbstractWe sought to examine the potential modifiers in the association between long-term low-dose folic acid supplementation and the reduction of serum total homocysteine (tHcy) among hypertensive patients, using data from the China Stroke Primary Prevention Trial (CSPPT). This analysis included 16 867 participants who had complete data on tHcy measurements at both the baseline and exit visit. After a median treatment period of 4·5 years, folic acid treatment significantly reduced the tHcy levels by 1·6 μmol/l (95 % CI 1·4, 1·8). More importantly, after adjustment for baseline tHcy and other important covariates, a greater degree of tHcy reduction was observed in certain subgroups: males, the methylenetetrahydrofolate reductase (MTHFR) 677TT genotype, higher baseline tHcy levels (≥12·5 (median) v. <12·5 μmol/l), lower folate levels (<8·0 (median) v. ≥8·0 ng/ml), estimated glomerular filtration rate (eGFR) <60 ml/min per 1·73 m2 (v. 60–<90 and ≥90 ml/min per 1·73 m2), ever smokers and concomitant use of diuretics (P for all interactions <0·05). The degree of tHcy reduction associated with long-term folic acid supplementation can be significantly affected by sex, MTHFR C677T genotypes, baseline folate, tHcy, eGFR levels and smoking status.

Low-dose folic acid supplementation reduces homocysteine concentration in hyperhomocysteinemic coronary artery disease patients

2006 ◽  
Vol 26 (9) ◽  
pp. 460-466 ◽  
Author(s):  
Ping-Ting Lin ◽  
Bor-Jen Lee ◽  
Han-Hsin Chang ◽  
Chien-Hsiang Cheng ◽  
An-Jung Tsai ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Folic Acid ◽  
Coronary Artery ◽  
Low Dose ◽  
Folic Acid Supplementation ◽  
Acid Supplementation ◽  
Homocysteine Concentration ◽  
Artery Disease

Longitudinal Change in Plasma Total Homocysteine During Pregnancy and Postpartum in Brazilian Women and its Relation with Folate Status and Other Factors

2004 ◽  
Vol 74 (2) ◽  
pp. 95-101 ◽  
Author(s):  
Glorimar ◽  
Pereira ◽  
Trugo
Keyword(s):  
First Trimester ◽  
Longitudinal Change ◽  
Plasma Vitamin ◽  
Dietary Intakes ◽  
Third Trimester ◽  
Folate Supplement ◽  
Pregnancy And Postpartum ◽  
Erythrocyte Folate ◽  
Total Homocysteine ◽  
Plasma Total Homocysteine

Abstract: Fasting plasma total homocysteine (tHcy) concentration was determined in a cohort of pregnant Brazilian women (n = 46) supplemented with folic acid from the second trimester of pregnancy. Blood samples were obtained in the first and third trimesters from all women, and 30–40 days postpartum from seventeen women. Plasma tHcy decreased during pregnancy from 10.3 to 8.7 mumol/L, and was 11.6 mumol/L in the postpartum. Plasma and erythrocyte folate increased, consistent with use of the folate supplement, but decreased slightly in the postpartum, whereas the opposite occurred for plasma vitamin B12. tHcy was inversely correlated with plasma and erythrocyte folate in the third trimester (r = –0.585 and –0.460, respectively). This relationship occurred despite the fact that all women had attained what could be considered adequate levels of folate indices. Furthermore, the change (third trimester minus first trimester levels) of tHcy was inversely correlated (p < 0.01) with the changes in plasma (r = –0.573) and erythrocyte folate (r = –0.525). tHcy had no correlation in any of the periods tested with plasma vitamin B12, plasma albumin, hematocrit, hemoglobin, iron indices, dietary intakes of folate, vitamins B12 and B6, and levels of folate supplement.

scholarly journals The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

1990 ◽  
Vol 33 (1) ◽  
pp. 9-18 ◽  
Author(s):  
Sarah L. Morgan ◽  
Joseph E. Baggott ◽  
William H. Vaughn ◽  
Peggy K. Young ◽  
Janet V. Austin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Folic Acid ◽  
Low Dose ◽  
Folic Acid Supplementation ◽  
Acid Supplementation ◽  
Dose Methotrexate

scholarly journals B vitamins for stroke prevention

2018 ◽  
Vol 3 (2) ◽  
pp. 51-58 ◽  
Author(s):  
Graeme J Hankey
Keyword(s):  
Clinical Trials ◽  
Folic Acid ◽  
Stroke Prevention ◽  
Stroke Risk ◽  
Folic Acid Supplementation ◽  
Adverse Outcomes ◽  
B Vitamins ◽  
Vitamin B ◽  
Folate Supplementation ◽  
Acid Supplementation

Supplementation with B vitamins (vitamin B9(folic acid), vitamin B12 and vitamin B6) lowers blood total homocysteine (tHcy) concentrations by about 25% and reduces the relative risk of stroke overall by about 10% (risk ratio (RR) 0.90, 95% CI 0.82 to 0.99) compared with placebo. Homocysteine-lowering interventions have no significant effect on myocardial infarction, death from any cause or adverse outcomes. Factors that appear to modify the effect of B vitamins on stroke risk include low folic acid status, high tHcy, high cyanocobalamin dose in patients with impaired renal function and concurrent antiplatelet therapy. In regions with increasing levels or established policies of population folate supplementation, evidence from observational genetic epidemiological studies and randomised controlled clinical trials is concordant in suggesting an absence of benefit from lowering of homocysteine with folic acid for prevention of stroke. Clinical trials indicate that in countries which mandate folic acid fortification of food, folic acid supplementation has no significant effect on reducing stroke risk (RR 1.05, 95% CI 0.90 to 1.23). However, in countries without mandatory folic acid food fortification, folic acid supplementation reduces the risk of stroke by about 15% (RR 0.85, 95% CI 0.77 to 0.94). Folic acid alone or in combination with minimal cyanocobalamin (≤0.05 mg/day) is associated with an even greater reduction in risk of future stroke by 25% (RR 0.75, 95% CI 0.66 to 0.86), whereas the combination of folic acid and a higher dose of cyanocobalamin (≥0.4 mg/day) is not associated with a reduced risk of future stroke (RR 0.95, 95% CI 0.86 to 1.05). The lack of benefit of folic acid plus higher doses of cyanocobalamin (≥0.4 mg/day) was observed in trials which all included participants with chronic kidney disease. Because metabolic B12 deficiency is very common and usually not diagnosed, future randomised trials of homocysteine-lowering interventions for stroke prevention should probably test a combination of folic acid and methylcobalamin or hydroxocobalamin instead of cyanocobalamin, and perhaps vitamin B6.

Sign in / Sign up

Export Citation Format

Share Document